48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit
Key Milestone Achieved with Dosing of the First Patient in Phase 1 Part 3 16-Week Titration Study Evaluating 48 mg (1-Step) and 64 mg (2-Step) Regimens; Data Expected in Fourth Quarter 2026
CAMBRIDGE, Mass., May 14, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate strategic update.
"We continued to build strong momentum in the first quarter of 2026 and most recently, as highlighted by the on-time dosing of the first patient in Part 3 of our Phase 1 clinical trial of DA-1726 for obesity, which followed closely on the heels of receiving IRB approval," said Hyung Heon Kim, Chief Executive Officer of MetaVia. "In this part of the trial, we are evaluating higher doses through optimized titration regimens, including a one-step escalation to 48 mg and a two-step escalation to 64 mg. This strategy is intended to safely reach higher therapeutic doses with improved tolerability, which could represent a meaningful advantage compared to currently marketed therapies that require longer, more gradual titration. Our January financing provides the capital to support the execution of this study, and we look forward to reporting data from Part 3 in the fourth quarter of 2026."
"This trial is designed to build on the compelling results reported in January from the 8-week, non-titrated 48 mg cohort, which demonstrated robust early weight loss of 9.1%, statistically significant reductions in waist circumference, meaningful improvements in glucose control and direct liver benefit, all with a favorable safety and tolerability profile. Based on these results, we believe DA-1726 has the potential to establish a best-in-class profile in obesity and broader cardiometabolic disease, driven by its differentiated dual GLP-1/glucagon mechanism. We also look forward to presenting additional data from the Phase 1 48 mg dose cohort on the direct liver benefit of DA-1726 at the European Association for the Study of the Liver (EASL) Congress 2026."
First Quarter 2026 and Subsequent Highlights
-- May 2026: Announced the presentation of additional data from the 48 mg
Phase 1 trial of DA-1726 at the EASL Congress 2026 in a poster entitled,
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726,
an Oxyntomodulin Analogue, in a Higher-Dose Phase 1 Cohort with
Exploratory Noninvasive Liver Assessment.
-- April 2026: Dosed the first patient in Part 3 of the Phase 1 clinical
trial evaluating DA-1726 in obese, otherwise healthy adults, consisting
of two 16-week titration cohorts designed to evaluate one-step dose
titration to 48 mg and two-step dose titration to 64 mg, designed to
safely achieve higher target doses and further optimize tolerability.
-- March 2026: Received IRB approval from Clinical Pharmacology of Miami for
the Phase 1 Part 3 16-week titration study of DA-1726.
-- March 2026: Announced a comprehensive global intellectual property
portfolio supporting vanoglipel with 48 granted and pending patents
across three patent families in the U.S., Europe, Japan, China and other
countries, providing protection into 2035, unless extended further.
Exclusively licensed from Dong-A ST Co., Ltd., the patent portfolio
provides broad protection for vanoglipel itself, how it is manufactured,
and its potential use across a range of serious metabolic and liver
conditions.
-- February 2026: Strengthened global intellectual property position for
DA-1726 with 39 granted and pending patents in the U.S. and
internationally, providing protection through at least 2041, unless
extended further. Exclusively licensed from Dong-A ST Co., Ltd., the
portfolio broadly covers DA-1726's novel peptide structure, its
long-acting dual-incretin design, and therapeutic use across obesity,
metabolic disease, and related cardiometabolic conditions.
-- February 2026: Announced positive AI-modeling results from the ongoing
collaboration with Syntekabio, Inc., an AI-driven drug discovery company,
leveraging their proprietary DeepMatcher$(R)$ platform. The results
confirmed vanoglipel's strong inflammatory and cardiometabolic target
engagement, supporting development in MASH and, potentially, type 2
diabetes.
-- January 2026: Closed an underwritten public offering of shares of common
stock, pre-funded warrants, Series C Common Warrants and Series D Common
Warrants for gross proceeds of approximately $9.3 million, prior to
deducting underwriting discounts and commissions and offering expenses
and excluding any potential future proceeds from the exercise of
warrants.
-- January 2026: Announced positive, statistically significant results from
the 8-week (extended from four weeks) non-titrated 48 mg MAD cohort of
the Phase 1 clinical trial of DA-1726. The results showed robust early
weight loss, statistically significant reductions in waist circumference,
strong improvements in glucose control, and meaningful reductions in
liver stiffness, alongside a favorable safety and tolerability profile.
Anticipated Clinical Milestones
-- DA-1726 in Obesity:
-- Data readout from Phase 1 Part 3, 16-week titration studies,
evaluating titration to 48 mg in one step and 64 mg via a two-step
regimen, is expected in the fourth quarter of 2026.
-- Vanoglipel (DA-1241) in MASH:
-- The Company is currently working to schedule an end-of-Phase 2
meeting with the FDA.
First Quarter Financial and Operating Results
-- Research and Development (R&D) Expenses were approximately $2.1 million
for the first quarter ended March 31, 2026, as compared to approximately
$2.3 million for the first quarter ended March 31, 2025. The decrease of
approximately $0.2 million was primarily attributable to (i) $0.1 million
in lower direct R&D expenses related to vanoglipel product development
and (ii) $0.1 million in lower indirect employee compensation and
benefits costs. Included in direct R&D costs were expenses totaling $0.7
million and $1.1 million for the three months ended March 31, 2026 and
2025, respectively, related to investigational drug manufacturing,
non-clinical and preclinical costs incurred under the Shared Services
Agreement with Dong-A ST (related party).
-- General and Administrative (G&A) Expenses were approximately $1.9 million
for the first quarter ended March 31, 2026, as compared to approximately
$1.6 million for the first quarter ended March 31, 2025. The
approximately $0.3 million increase was primarily attributable to (i)
approximately $0.1 million in higher consulting expenditures, (ii)
approximately $0.1 million in higher franchise tax expenses, and (iii)
$0.1 million in higher legal and professional fees.
-- Total Operating Expenses were approximately $4.0 million for the first
quarter ended March 31, 2026, compared to approximately $3.9 million for
the first quarter ended March 31, 2025. The approximately $0.1 million
increase was primarily attributable to higher G&A expenses and was
partially offset by lower R&D expenses.
-- Total Other Income was approximately $0.2 million for the first quarter
ended March 31, 2026, consistent with the corresponding period in 2025.
-- Net Loss was $3.8 million, or $0.79 per basic and diluted share, for the
first quarter ended March 31, 2026 based on 4,859,567 weighted average
shares of common stock outstanding, compared with a net loss of $3.7
million, or $3.93 per basic and diluted share, based on 933,109 weighted
average shares of common stock outstanding for the first quarter ended
March 31, 2025.
-- Cash and cash equivalents was $13.7 million as of March 31, 2026,
compared with $10.2 million as of December 31, 2025. The company expects
its cash position will be adequate to fund operations into the fourth
quarter of 2026.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin $(OXM)$ analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com.
Forward Looking Statements
(MORE TO FOLLOW) Dow Jones Newswires
May 14, 2026 16:05 ET (20:05 GMT)
Comments